Plasma-Based Diagnostics for Alzheimer's Disease: Current State and Clinical Relevance of pTau 217

Course overview

In the past three years, rapid advancement has been made in the diagnosis and treatment of Alzheimer's disease (AD). We will review updated AD diagnostic criteria with a biomarker framework in mind and with special focus on fluid biomarkers, including phosphorylated tau 217 (pTau 217), an AD blood-based biomarker. Using clinical cases as a guide, we will help you understand the role of pTau 217 in the diagnosis and treatment of AD. After this presentation, participants will be able to: 1) Explain recent changes in AD diagnostic criteria 2) Describe the role of fluid biomarkers in the diagnosis of AD 3) Summarize the sequence of biomarker changes across the disease course in AD 4) Select patients appropriate for pTau 217 testing